Utama › Karsinoma Epitel Ovari › Oregon
Kajian klinikal Karsinoma Epitel Ovari di Oregon
6 kajian untuk Karsinoma Epitel Ovari sedang mencari peserta di lokasi di Oregon.
Bandar di Oregon
Teks kajian rasmi (Bahasa Inggeris)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
- Compass Oncology - West - Tigard /ID# 275101, Tigard
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05867251Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Providence Cancer Institute, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 15 Sep 2026 · NCT06915025AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 21 Jul 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Legacy Medical Group Gynecologic Oncology, Portland
- Providence Cancer Center Oncology, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 2 Jul 2026 · NCT06819007CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Northwest Cancer Specialists, P.C., Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 23 Dis 2025 · NCT06690775Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.